T. R. Malek and I. Castro, Interleukin-2 receptor signaling: at the iterface between tolerance and immunity, Immunity, vol.33, pp.153-65, 2010.

D. Klatzmann and A. K. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases, Nat Rev Immunol, vol.15, pp.283-94, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01617541

A. Yu, I. Snowhite, F. Vendrame, M. Rosenzwajg, D. Klatzmann et al., Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes, Diabetes, vol.64, pp.2172-83, 2015.

D. Saadoun, M. Rosenzwajg, F. Joly, A. Six, F. Carrat et al., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis, N Engl J Med, vol.365, pp.2067-77, 2011.

B. Bonnet, J. Vigneron, B. Levacher, T. Vazquez, F. Pitoiset et al., Low-dose IL-2 induces regulatory T cell-mediated control of experimental food allergy, J Immunol, vol.197, pp.188-98, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01617587

J. Koreth, K. Matsuoka, H. T. Kim, S. M. Mcdonough, B. Bindra et al., Interleukin-2 and regulatory T cells in graft-versus-host disease, N Engl J Med, vol.365, pp.2055-66, 2011.

M. W. Konrad, G. Hemstreet, E. M. Hersh, P. W. Mansell, R. Mertelsmann et al., Pharmacokinetics of recombinant interleukin 2 in humans, Cancer Res, vol.50, pp.2009-2026, 1990.

M. Rosenzwajg, G. Churlaud, R. Mallone, A. Six, and W. Chaara, Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients, J Autoimmun, vol.58, pp.48-58, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01112156

A. Hartemann, G. Bensimon, C. A. Payan, S. Jacqueminet, O. Bourron et al., Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial, Lancet Diabetes Endocrinol, vol.1, pp.295-305, 2013.

T. Transreg, . D. Prof, M. D. Klatzmann, and P. Methodologist, PharmD Clinicians and recruiting centers-Department of Gastroenterology, PhD Biological Investigation: M. Rosenzwajg, MD Modeling and Interim Analysis Clinical Pharmacology

A. Department-of-rheumatology and P. , Salp^ etri ere Hospital (Prof. B. Fautrel, MD, PhD); Department of Dermatology

M. D. , B. Charbit, M. D. , N. Nicolas, M. D. et al., MD, PhD) THE DF-IL2 STUDY GROUP Principal Investigator: Prof. D. Klatzmann, MD, PhD Principal Clinical Investigator: Prof A. Hartemann, MD Methodologist: G. Bensimon, MD Data Management & Statistical Analysis: C. A. Payan, MD Clinical Investigations Center-Centre d'Investigation Clinique

N. Dedise, C. , and D. W. Gu, PhD Treatment Management Pharmacy, Piti e-Salp^ etri ere Hospital, AP-HP

M. Raffin-sanson, A. Md);-department-of-diabetology, and H. Hospital, Piti e-Salp^ etri ere Hospital, AP-HP

N. Bourcigaux, M. D. , E. Laroche, M. D. , and S. Christin-maitre, MD

F. E. , Dynamics and modeling of Treg cells in mice treated with IL2. Results are expressed as relative variation compared with the PBS-treated group. These data are from a pool of 3 different experiments (n 5 10) using C57BL/6 mice. Treg-cell dynamics in blood at 2 and 24 hours postinjection (A) and Treg-cell dynamics in blood and spleen at 2 hours postinjection (B)

C. , Dynamics of Treg cells in blood during a 5-day course of 50,000 IU of IL-2 and then reinjection every 3, 7, or 15 days with 50,000 IU of IL-2. Comparison between IL-2 and PBS groups was done using the Mann-Whitney test

*. ,

*. , , vol.0001